Your cholesterol is already doing something to your brain.
A one-time gene edit dropped LDL by up to 62% and held it for 18 months. It is years from a clinic. The number underneath LDL, ApoB, is something you can measure this month.
A particle count, not a cholesterol score.
LDL-C tells you how much cholesterol is being carried inside LDL particles. ApoB tells you how many particles there actually are. Since it is the particles that lodge in artery walls and start plaque, ApoB is the better predictor of risk. When the two numbers disagree, ApoB is the one to trust.
Among BetterBrain clients, 86% come back with a suboptimal ApoB. It is the single most commonly out-of-range marker we see, and it is rarely ordered unless you ask for it.
What brought you here?
Three ways in, one page. Pick the one that sounds like you.
A number worth having, for reasons beyond your heart.
ApoB is not part of a standard lipid panel and usually has to be requested. The question is not whether you can get it, but what you would do with it once you have it.
See everything we test ↗Do not stop at the lipid panel.
You do not have to wait for a therapy that is years away. The target itself, your lipid health, is measurable and movable today.
A routine lipid panel gives you total cholesterol, LDL, HDL and triglycerides. ApoB counts the particles actually driving damage, and is rarely ordered unless you ask for it.
ApoB, Lp(a), triglycerides, blood pressure and HbA1c interact. One number in isolation rarely tells you what to do first.
Risk accumulates over decades, so small steady improvements compound in your favor. Diet, regular movement and, where your physician recommends them, proven lipid-lowering medications all work today.
The headline number needs a footnote.
Heart-2 is a phase 1b trial: 35 participants, average age 52, all with inherited high cholesterol or premature coronary artery disease, and all already on the maximum statin dose they could tolerate. It has not been shown to prevent heart attacks, strokes, or cognitive decline.
Read the study ↗Know which number you are reading.
Two people can have the same LDL-C with very different particle counts. The measurement you were given decides what the result can tell you.
Every LDL particle carries exactly one ApoB protein, so ApoB counts the particles rather than the cholesterol inside them. BetterBrain reads it alongside homocysteine, hs-CRP, Lp(a), HbA1c and the rest of the vascular and metabolic markers, with a cognitive baseline and expert review.
Information is one input. The plan is the product.
BetterBrain does not hand you a number and wish you luck. Every result is read inside a system built to explain what it means for you, and where you can take meaningful action.
There is more to brain health than one marker.
The 2024 Lancet Commission estimates that addressing 14 modifiable risk factors across life could prevent or delay around 45% of dementia cases at the population level. The useful question is where your own margin lies.
Review the evidence ↗Clear answers, without false certainty.
No. VERVE-102 is in phase 1b trials. A phase 2 trial is planned to begin enrolling by the end of 2026, and broad availability is years out. If it is approved, the first patients are likely to be people with familial hypercholesterolemia or other very high-risk conditions.
Your lipid numbers are one of the few brain risk factors you can act on today.
Whatever arrives in five or ten years, the decades in between are the ones you protect now. ApoB is one of the 50+ markers in the BetterBrain panel, read with a cognitive baseline, expert interpretation and a personalized action plan.